fireflyneuro.com (AIFF) - Long-Term Liabilities to Capital

Firefly Neuro - graphic logo of issuer AIFF

The current long-term debt-to-equity ratio for Firefly Neuroscience, Inc (AIFF) shows that the latest figure is 0.00. Firefly Neuroscience, Inc (AIFF) is implementing BNA AI analysis for the objective diagnosis of mental disorders via digital biomarkers. Redundant US cloud data centers ensure the stability of B2B services. Simultaneously, the company is deploying the BrainScope system, which automates high-precision scanning of brain functions.

Firefly Neuroscience, Inc. (AIFF): Long-Term Debt to Equity from 07/04/2022 to 10/30/2026

Comprehensive metric breakdowns and analytics for Firefly Neuroscience, Inc (AIFF)

- current price and projected stock value:
Share Price Firefly Neuroscience, Inc.|AIFF - Analyst Consensus Forecast
- market capitalization indicators:
Market Value Firefly Neuroscience, Inc.|AIFF - Real Price to Acquire Entire Company
- book value of equity indicators:
Book Value per Share Firefly Neuroscience|AIFF - Company Book Value|Market Value to Book Value fireflyneuro.com|AIFF - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Capital Firefly Neuroscience, Inc|AIFF - Long-Term Debt to Capital|Current Liabilities to Equity fireflyneuro.com|AIFF - Company Aggregate Debts|Debts to Net Assets Firefly Neuroscience, Inc.|AIFF - Company Long-Term Debt|Company Short-Term Loans and Borrowings Firefly Neuroscience|Immediate Liquidity fireflyneuro.com
- net income and valuation ratios data:
AIFF - Net Profit
Summary company analysis:Firefly Neuroscience, Inc
Original product of Firefly Neuro

This indicator compares long-term liabilities to total equity, determining the extent to which financial stability depends on external financing. The metric measures the issuer's ability to service loans with a maturity of over one year without compromising profitability. For Firefly Neuroscience, Inc (AIFF), such borrowings could support the scaling of its cloud-based EEG analysis platform. By analyzing the ratio of long-term loans to equity, an investor assesses the balance between investment growth and debt load.

Analysis of competing companies

Long-Term Debt to Capital Ratio BIIB (Biogen Inc)|Long-Term Debt to Capital NBIX|RGC - Long-Term Liabilities to Capital|Axsome Therapeutics - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital acadia-pharm.com ACAD|XENE - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient VKTX (Viking Therapeutics Inc)|Supernus Pharma (SUPN) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Catalyst Corp (CPRX)|DNLI (Denali Therapeutics) - Long-Term Debt to Capital|harmonybiosciences.com - Long-Term Liabilities to Equity|Long-Term Debt to Capital BHVN|Ratio of Long-Term Indebtedness to Capital Amylyx Pharmaceuticals Inc|Long-Term Debt to Equity Trevi Pharma TRVI|Long-Term Debt to Capital Coefficient PRAX|Anavex Life Sciences - Long-Term Debt to Capital|Long-Term Liabilities to Capital ceribell.com|PRTA: Long-Term Debt to Capital|Long-Term Liabilities to Equity ALEC (Alector)|Long-Term Debt to Equity Annexon Inc.|Long-Term Debt to Equity OMER|Long-Term Debt to Equity Ratio NGNE (Neurogene Inc.)|ACIU - Long-Term Liabilities to Capital|Voyager Therapeutics, Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient NMRA|SCLX - Long-Term Debt to Equity|TVGN (Tevogen Bio Inc.) - Long-Term Debt to Capital Ratio|ACOG: Long-Term Debt to Capital|Long-Term Liabilities to Capital cogrx.com (CGTX)|Long-Term Debt to Equity Ratio IKT|Long-Term Debt to Capital Cassava Sciences Inc|Long-Term Debt to Equity Assertio Holdings, Inc. (ASRT)|COYA (coyatherapeutics.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Vistagen VTGN|Ovid Therapeutics Inc (OVID) - Long-Term Liabilities to Capital|ABOS - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital CervoMed, Inc. CRVO|ATHE: Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Clene|PEPG (PepGen Inc) - Long-Term Debt to Capital|jupiterneurosciences.com (JUNS) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Capital RLMD|ANVS - Long-Term Liabilities to Capital|Long-Term Debt to Equity Grace Therapeutics GRCE|KLTO: Long-Term Debt to Capital Ratio|NeuroSense Therapeutics, Ltd. - Long-Term Debt to Capital|revivapharma.com (RVPH) - Long-Term Debt to Equity Ratio|MTVA: Long-Term Debt to Capital|Long-Term Liabilities to Capital NeurAxis Inc. (NRXS)|Long-Term Debt to Equity Ratio HSDT|PASG: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital NEUP|Ratio of Long-Term Indebtedness to Capital minervaneurosciences.com|Long-Term Debt to Equity Athira Pharma ATHA|ADXN: Long-Term Debt to Capital Ratio|Alzamend - Long-Term Debt to Capital|Cyclerion Therapeutics (CYCN) - Long-Term Debt to Equity Ratio|PTIX: Long-Term Debt to Capital|Pasithea Therapeutics Corp. (KTTA) - Long-Term Debt to Capital|CRGT (Cortigent Inc) - Long-Term Debt to Capital|Avenue Therapeutics Inc. (ATXI) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Capital BCLI|CARA: Long-Term Liabilities to Equity|Long-Term Debt to Capital CHRO (Chromocell Therapeutics)|ELYM (Eliem Therapeutics, Inc.) - Long-Term Liabilities to Equity|ITCI - Long-Term Debt to Equity|LBPH (Longboard Pharmaceuticals Inc) - Long-Term Debt to Capital Ratio|MRNS: Long-Term Debt to Capital|Long-Term Liabilities to Capital NKGen Biotech Corp (NKGN)|Long-Term Debt to Equity Ratio NRBO|Long-Term Debt to Capital sagerx.com|Long-Term Debt to Equity Synaptogenix (SNPX)|TRVN (Trevena Inc.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Vigil Neuroscience, Inc. VIGL|Anew Medical Inc. (WENA) - Long-Term Liabilities to Capital|Cerevel Therapeutics - Long-Term Debt to Capital